Status: Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
Participants needed: 600
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: BioAegis Therapeutics Inc.Updated: Jun 15, 2026Locations: 70
Eligibility criteria
Infection followed within a week of documented bilateral infiltrates/opacities c... [+10]
Ongoing evidence or suspicion that heart failure, volume overload, pulmonary emb... [+12]